Translational Research and Specialty Diagnostic Laboratory, Arnold Palmer Hospital for Children, Orlando Health, 110 Bonnie Loch Court, Orlando, FL, 32806, USA.
Nano Discovery Inc., 1060 Woodcock Road Suite 131, Orlando, FL, 32803, USA.
Sci Rep. 2021 Dec 6;11(1):23491. doi: 10.1038/s41598-021-02863-2.
Upon infection with SARS-CoV-2, the virus that causes COVID-19, most people will develop no or mild symptoms. However, a small percentage of the population will become severely ill, and some will succumb to death. The clinical severity of COVID-19 has a close connection to the dysregulation of the patient's immune functions. We previously developed a simple, nanoparticle-enabled blood test that can determine the humoral immune status in animals. In this study, we applied this new test to analyze the immune function in relation to disease severity in COVID-19 patients. From the testing of 153 COVID-19 patient samples and 142 negative controls, we detected a drastic decrease of humoral immunity in COVID-19 patients who developed moderate to severe symptoms, but not in patients with no or mild symptoms. The new test may be potentially used to monitor the immunity change and predict the clinical risk of patients with COVID-19.
当感染引起 COVID-19 的 SARS-CoV-2 病毒时，大多数人将没有或仅有轻微症状。然而，一小部分人群会病情严重，有些人会死亡。COVID-19 的临床严重程度与患者免疫功能的失调密切相关。我们之前开发了一种简单的、基于纳米颗粒的血液检测方法，可以确定动物的体液免疫状态。在这项研究中，我们应用这项新的检测方法来分析 COVID-19 患者与疾病严重程度相关的免疫功能。通过对 153 例 COVID-19 患者样本和 142 例阴性对照的检测，我们发现病情发展为中度至重度症状的 COVID-19 患者的体液免疫功能明显下降，但无或轻度症状的患者则没有这种情况。新的检测方法可能可用于监测免疫变化并预测 COVID-19 患者的临床风险。
